Medications for Lymphangioleiomyomatosis
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Lymphangioleiomyomatosis.
Found 1 Approved Drug for Lymphangioleiomyomatosis
SIrolimus
Brand Names
Rapamune, Hyftor, Fyarro
SIrolimus
Brand Names
Rapamune, Hyftor, Fyarro
Form: Gel, Injection, Tablet, Solution
Method of administration: Oral, Intravenous, Topical
FDA approval date: July 01, 2001
Classification: mTOR Inhibitor Immunosuppressant
Sirolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in patients aged ≥13 years receiving renal transplants. : Patients at low- to moderate-immunologic risk: Use initially with cyclosporine (CsA) and corticosteroids. CsA withdrawal is recommended 2 months to 4 months after transplantation.
Showing 1-1 of 1
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances